Abstracts Archive - Page 851 of 2425 - ACR Meeting Abstracts

Abstract Number: 1389 • 2019 ACR/ARP Annual Meeting
Treatment Response to Biologic DMARDs in Patients with RA: A Retrospective Analysis of the RISE Registry
Xue Han¹, Joshua Bryson ¹, David C Crosby ¹, Michael Evans ² and Gabriela Schmajuk ³, ¹Bristol-Myers Squibb, Princeton, ²University of California San Francisco, San Francisco, ³UCSF, SFVAMC Division of Rheumatology, San Francisco, CA
Background/Purpose: ACR guidelines recommend treatment for patients with RA based on baseline (BL) disease activity. In patients with an inadequate response to conventional synthetic DMARDs,…
Abstract Number: 1390 • 2019 ACR/ARP Annual Meeting
Prediction of Clinical Response to Abatacept in Rheumatoid Arthritis Patients Through the Determination of Anti-Carbamylated Proteins Antibodies Levels
Silvia Piantoni¹, Michele Boldini ¹, Rajesh Kumar ¹, Emirena Garrafa ¹, Chiara Bazzani ², Micaela Fredi ³, Ilaria Cavazzana ¹, Angela Tincani ³ and Franco Franceschini ³, ¹ASST Spedali Civili and University of Brescia, Brescia, Italy, ²Rheumatology and Clinical Immunology, Spedali Civili, Brescia, Italy, Brescia, Italy, ³Rheumatology and Clinical Immunology, Spedali Civili and Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy, Brescia, Italy
Background/Purpose: Carbamylation is a non-enzymatic irreversible post-translational modification of proteins. The presence of anti-carbamylated protein antibodies (anti-CarP) has been observed in rheumatoid arthritis (RA). In…
Abstract Number: 1391 • 2019 ACR/ARP Annual Meeting
Connective Tissue Remodeling Is Differently Modulated by Tocilizumab versus Methotrexate Monotherapy in Patients with Early RA: The AMBITION Study
Patryk Drobinski¹, Anne Bay-Jensen ², Morten Karsdal ³ and Anne Siebuhr ⁴, ¹University of Copenhagen/Nordic Bioscience, Copenhagen, Denmark, ²Nordic Bioscience, Herlev, Denmark, ³Nordic Bioscience, Copenhagen, Denmark, ⁴Nordic Bioscience, Herlev
Background/Purpose: Response to treatments in Rheumatoid Arthritis (RA) is assessed by symptomatic changes, such as ACR-response and DAS28. However, such assessments do not provide information…
Abstract Number: 1392 • 2019 ACR/ARP Annual Meeting
The Relationship Between Abatacept Exposure and CD86 Receptor Occupancy in Rheumatoid Arthritis Patients Following Subcutaneous Administration and Its Association to Patient Outcomes
Grigor Abelian¹, Sheng Gao ², Yash Gandhi ¹, Blisse Vakkalagadda ¹, Vidya Perera ¹ and Bindu Murthy ¹, ¹Bristol-Myers Squibb, Princeton, ²Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: The purpose of this investigation was to characterize the relationship between systemic exposure of abatacept and measures of target engagement to further support dosing…
Abstract Number: 1393 • 2019 ACR/ARP Annual Meeting
Impact of Sarilumab on Unacceptable Pain and Inflammation Control in Moderately-to-Severely Active Rheumatoid Arthritis (RA) Patients in 3 Phase 3 Studies
Vivian Bykerk¹, Wenhui Wei ², Susan Boklage ², Toshio Kimura ², Stefano Fiore ³ and Gregory St John ⁴, ¹Hospital for Special Surgery, New York City, NY, ²Regeneron Pharmaceuticals, Inc, Tarrytown, NY, ³Sanofi Genzyme, Bridgewater, NJ, ⁴Regeneron Pharmaceuticals, Inc., Tarrytown, NY
Background/Purpose: Pain, a core-set domain and a troubling symptom to patients with RA, may be directly related to inflammation. Unacceptable pain (UP) levels may persist…
Abstract Number: 1394 • 2019 ACR/ARP Annual Meeting
Association Between Baseline Anti-CCP2 Antibody Concentration and Clinical Response After 6 Months of Treatment with Abatacept or a TNF Inhibitor in Biologic-Experienced Patients with RA: Results from a US National Observational Study
Leslie Harrold ¹, Joshua Bryson², Thomas Lehman ³, Joe Zhuo ³, Sheng Gao ³, Xue Han ⁴, Amy Schrader ⁵, Sabrina Rebello ⁶ and Joel Kremer ⁷, ¹University of Massachusetts and Corrona, LLC, Waltham, MA, ²Bristol-Myers Squibb, Princeton, ³Bristol-Myers Squibb, Princeton, NJ, ⁴Bristol-Myers Squibb Company, Princeton, NJ, ⁵Corrona, LLC, Waltham, ⁶Corrona, LLC, Waltham, MA, ⁷Albany Medical College, Albany, NY
Background/Purpose: In the AMPLE trial, patients (pts) with RA with higher baseline anti-CCP2 antibody concentrations showed a better response to treatment with abatacept (ABA) than…
Abstract Number: 1395 • 2019 ACR/ARP Annual Meeting
Risk of Immunization to Rituximab in Systemic Autoimmune Diseases and Rheumatoid Arthritis: Frequency and Risk Factors. Analysis of the Efficacy of an Alternative Treatment by Ofatumumab
Alice Combier¹, Gaetane Nocturne ², Julien Henry ³, Rakiba Belkhir ¹, Stephan Pavy ⁴, Clotilde Le Tiec ⁵, Elise Descamps ⁴, Raphaele Seror ⁶ and Xavier Mariette ⁷, ¹Rheumatology Departement - Bicêtre Hospital, Paris, France, ²Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France., Paris, France, ³Rheumatology Departement - Bicêtre Hospital, Paris, ⁴Rheumatology Departement - Bicètre Hospital, Paris, France, ⁵Pharmacy Departement - Bicètre Hospital, Paris, France, ⁶Hopitaux universitaires Paris Sud, Kremlin-Bicetre, France, ⁷Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France
Background/Purpose: The most widely used B cell targeted therapies in auto-immune diseases (AID) is Rituximab (RTX), a murine chimeric monoclonal antibody. Among RTX’s side effects,…
Abstract Number: 1396 • 2019 ACR/ARP Annual Meeting
Persistence of Tocilizumab Therapy Among Patients with Rheumatoid Arthritis: Data from the US-Based Corrona Rheumatoid Arthritis Registry
Dimitrios Pappas¹, Taylor Blachley ², Jennie Best ³, Steve Zlotnick ³, Kelechi Emeanuru ² and Joel Kremer ⁴, ¹Columbia University, New York, NY, ²Corrona, LLC, Waltham, MA, ³Genentech, Inc., South San Francisco, CA, ⁴Albany Medical College and The Center for Rheumatology; Corrona, LLC, Albany, NY
Background/Purpose: Understanding persistence of biologic therapies and factors associated with discontinuation can help inform treatment decisions for patients with rheumatoid arthritis (RA). We sought to…
Abstract Number: 1397 • 2019 ACR/ARP Annual Meeting
Comparative Effectiveness of Tocilizumab in Combination with Methotrexate versus Tumor Necrosis Factor Inhibitors (TNFis) in Combination with Methotrexate in Patients with Rheumatoid Arthritis with Prior Exposure to TNFis
Dimitrios Pappas¹, Taylor Blachley ², Steve Zlotnick ³, Jennie Best ³, Kelechi Emeanuru ² and Joel Kremer ⁴, ¹Columbia University, New York, NY, ²Corrona, LLC, Waltham, MA, ³Genentech, Inc., South San Francisco, CA, ⁴Albany Medical College and The Center for Rheumatology; Corrona, LLC, Albany, NY
Background/Purpose: Clinical studies have demonstrated the efficacy of tocilizumab (TCZ) administered with methotrexate (MTX) in improving rheumatoid arthritis (RA) disease activity in patients who have…
Abstract Number: 1398 • 2019 ACR/ARP Annual Meeting
Sarilumab and Tocilizumab Receptor Occupancy (RO), and Effects on C-Reactive Protein (CRP) Levels, in Patients with Rheumatoid Arthritis (RA)
Christine Xu¹, Patrick Nolain ², Qiang Lu ³, Anne Paccaly ⁴, Melitza Iglesias-Rodriguez ⁵, Gregory St John ⁶, Chad Nivens ⁴, Rafael Maldonado ⁷, Tomonori Ishii ⁸, Ernest Choy ⁹ and Vanaja Kanamaluru ³, ¹Sanofi, Bridgewater, NJ, ²Sanofi-Aventis, Montpellier, France, ³Sanofi, Bridgewater, ⁴Regeneron Pharmaceuticals, Inc., Tarrytown, ⁵Sanofi Genzyme, Cambridge, MA, ⁶Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁷Pompeu Fabra University, Barcelona, Spain, ⁸Tohoku University Hospital, Sendai, Japan, ⁹Cardiff University School of Medicine, Cardiff, United Kingdom
Background/Purpose: The in vitro binding affinity of sarilumab (KD 61.9 pM) for the human interleukin-6 receptor (IL-6R) is 15–22-fold higher than that of tocilizumab. This…
Abstract Number: 1399 • 2019 ACR/ARP Annual Meeting
Evaluation of Effectiveness and Usage Patterns of Tofacitinib in Treatment of Rheumatoid Arthritis in Australia: An Analysis from the OPAL-QUMI Real World Dataset
Paul Bird¹, Geoffrey Littlejohn ², Belinda Butcher ³, Tegan Smith ⁴, Candida da Fonseca Pereira ⁵, David Witcombe ⁵ and Hedley Griffiths ⁶, ¹Optimus Research, Kogarah, New South Wales, Australia, ²Monash Rheumatology, Clayton, Victoria, Australia, ³WriteSource Medical Pty Ltd, Lane Cove, New South Wales, Australia, ⁴OPAL Rheumatology Ltd, Sydney, New South Wales, Australia, ⁵Pfizer Australia, Sydney, New South Wales, Australia, ⁶Barwon Rheumatology Service, Geelong, Victoria, Australia
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Limited data from large real-world patient populations exist to describe…
Abstract Number: 1400 • 2019 ACR/ARP Annual Meeting
Real Life Retention of Tofacitinib in Patients with Rheumatoid Arthritis
Aniela Croiteru ¹, Merav Lidar ², Tatiana Reitblat³, Devy Zisman ⁴, Alexandra Balbir-Gurman ⁵, Tanya Meshiach ⁵, Ronit Almog ⁵ and Ori Elkayam ⁶, ¹Tel Aviv medical center, Tel Aviv, Israel, ²Sheba Medical Center, Ramat Gan, Israel, ³Barzilai Medical Center, Ashkelon, Israel, ⁴Carmel Hospital and Ruth and Bruce Rappaport Faculty of Medicine, Technion, Israel, Haifa, Israel, ⁵Rambam Medical Center, Haifa, Israel, ⁶Rheumatology Department, Tel Aviv Medical Center, and Sackler Faculty of Medicine, Tel Aviv University, Israel., Tel Aviv, Israel
Background/Purpose: Tofacitinib (Xeljanz) is an approved treatment for Rheumatoid Arthritis (RA) but data on its use in “real life” are limited. We sought to analyze…
Abstract Number: 1401 • 2019 ACR/ARP Annual Meeting
Australian Rheumatoid Arthritis (RA) Biologic Treatment Pathways: An Australian Rheumatology Association Database (ARAD) Analysis
Ashley Fletcher ¹, Marissa Lassere², Lyn March ³, Catherine Hill ⁴, Claire Barrett ⁵, Graeme Carroll ⁶ and Rachelle Buchbinder ¹, ¹Cabrini Health/Monash University, Melbourne, Australia, ²St George Hospital, University of New South Wales, Sydney, Australia, ³University of Sydney, Sydney, Australia, ⁴Royal Adelaide Hospital/The University of Adelaide/The Queen Elizabeth Hospital, Adelaide, Australia, ⁵Redcliffe Hospital, University of Queensland, Redcliffe, Australia, ⁶Fiona Stanley Hospital, Perth, Australia
Background/Purpose: To describe current biologic disease-modifying antirheumatic drug (bDMARD) treatment patterns for Australian Rheumatology Association Database (ARAD) participants with Rheumatoid Arthritis (RA) including switching and…
Abstract Number: 1402 • 2019 ACR/ARP Annual Meeting
Efficacy, Safety and Continuation Rate of Abatacept and Tocilizumab in Patients with Rheumatoid Arthritis : The Comparative Observational Study
Mayumi Matsuda¹, Yu Funakubo Asanuma ¹, Takuma Wada ², Noritsune Kouzu ³, Kojiro Sato ⁴ and Toshihide Mimura ¹, ¹Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, ²Saitama Medical University, Saitama, Japan, ³Medical Kouzu orthopedic and Yachiyo radiation center, Chiba, Japan, ⁴Division of Rheumatology and Clinical Immunology, Department of Medicine, Jichi Medical University, Tochigi, Japan
Background/Purpose: Biologic agents used in patients with rheumatoid arthritis (RA) have increased in recent years. Abatacept (ABT) has been described as relatively safe for elderly…
Abstract Number: 1403 • 2019 ACR/ARP Annual Meeting
CDAI Analysis of Dose Escalation in a Trial of Infliximab for Rheumatoid Arthritis
John Tesser¹, Shawn Black ², Rongshuang Lin ³, Wayne Langholff ³, Jonathan Uy ⁴ and Shelly Kafka ⁴, ¹Arizona Arthritis and Rheumatology Associate, Phoenix, AZ, ²Janssen Scientific Affairs, LLC, Horsham, RI, ³Janssen Research & Development, LLC, Spring House, PA, ⁴Janssen Scientific Affairs, LLC, Horsham, PA
Background/Purpose: In the START (Safety Trial for Rheumatoid Arthritis with Remicade Therapy) trial, patients (pts) with active rheumatoid arthritis (RA) received placebo (PBO), or infliximab…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].